BICO Group AB Class B (49Z) AI Stock Analysis

14 Followers

BICO Group AB Class B

(XETRA:49Z)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Precision-biology strategyThe sharper focus on precision biology and 3D cell models could improve capital allocation by concentrating resources where BICO sees stronger competitive advantages. Over time, this may support more differentiated products, better returns on R&D, and a clearer path to profitable organic growth.

Negative Factors

Persistent unprofitabilityImproved gross margin has not yet translated into sustainable earnings because operating costs and other items continue to outweigh gross profit. Persistent losses limit internal funding capacity, weaken returns on equity, and leave profitability dependent on further execution and cost improvements.

BICO Group AB Class B (49Z) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 175.62M
Dividend Yield: ―
Average Volume (3M): 2,535
Price to Earnings (P/E): -5.2
Beta (1Y): 0.98
Revenue Growth: -2.54%
EPS Growth: 34.44%
Country: Germany
Employees: 554
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

BICO Group AB Class B Business Overview & Revenue Model

Company Description

BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. T...

BICO Group AB Class B Earnings Call Summary

Earnings Call Date:Nov 11, 2026(Q3-2026)|% Change Since:-32.89%|Next Earnings Date:Feb 25, 2021

Earnings Call SentimentNeutral

The call presented a strong Q3 with 19% organic sales growth, 14% growth in own benchtop instruments, a 27% adjusted EBITDA margin, restructuring progress, and a clear new precision-biology strategy. However, reported profitability benefited materially from a one-time SCIENION agreement, operating cash flow was negative, working capital was elevated, academic demand remained weak, and Biosero required a substantial SEK 296 million impairment and strategic reassessment. Overall, the positive operating momentum and strategic clarity were offset by significant execution, cash conversion, and Biosero-related challenges.

Positive Updates

Strong Q3 Revenue Growth

Net sales reached SEK 465 million, increasing 20% quarter-over-quarter and 19% organically.

Negative Updates

Biosero Underperformed and Strategic Direction Was Reset

BICO stated that it did not deliver on all BICO 2.0 ambitions, particularly scaling Biosero into the envisioned growth platform. Biosero sales and order intake declined, and larger legacy projects proved less profitable than anticipated as they were completed. BICO is assessing strategic options for Biosero's long-term path.

Company Guidance

BICO reconfirmed its long-term financial targets of double-digit organic growth in constant currencies, an EBITDA margin less capitalized development costs above 10%, and net debt-to-EBITDA below 3x, with new long-term financial targets to be defined once the current targets have been achieved. The restructuring program is expected to generate around SEK 30 million in annual savings, with the full effect expected later in Q4. Management said it does not give forecasts, expects the margin to be around the same level, and will ramp up for key product launches in 2027.

BICO Group AB Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:49Z against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CEVI	83Outperform	SEK 4.83B	34.95	15.23%	1.36%	1.95%	-8.91%
SE:BONEX	81Outperform	SEK 21.10B	76.71	29.00%	―	25.20%	79.34%
SE:XVIVO	64Neutral	SEK 6.49B	49.58	5.89%	―	17.83%	330.94%
SE:VITR	63Neutral	SEK 16.02B	-3.22	-61.57%	0.93%	-1.94%	-1223.74%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:OSSD	45Neutral	SEK 405.44M	-7.74	―	―	-11.89%	-11.85%

* Healthcare Sector Average

Performance Comparison

DE:49Z and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:49Z	BICO Group AB Class B	1.51	-0.25	-14.16%
SE:VITR	Vitrolife AB	119.20	-22.34	-15.79%
SE:BONEX	BONESUPPORT HOLDING AB	321.20	119.20	59.01%
SE:CEVI	CellaVision AB	203.50	48.94	31.66%
SE:XVIVO	Xvivo Perfusion AB	206.00	42.50	25.99%
SE:OSSD	OssDsign AB	3.50	-7.48	-68.12%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

BICO Group AB Class B AI Stock Analysis